```html

Kluyveromyces Infection – Complete Medical Guide

Overview

Kluyveromyces is a genus of yeasts that includes several species capable of causing opportunistic infections in humans, most notably Kluyveromyces marxianus and Kluyveromyces lactis. These organisms are found in dairy products, fermented foods, and the environment. While they are generally harmless to healthy individuals, they can cause invasive disease—especially bloodstream, urinary‑tract, or intra‑abdominal infections—in people with weakened immune systems.

• Who it affects: Primarily immunocompromised patients, including those with hematologic malignancies, solid‑organ transplants, HIV/AIDS, prolonged ICU stays, or receiving broad‑spectrum antibiotics or corticosteroids.
• Prevalence: Kluyveromyces infections are rare; case reports worldwide estimate < 0.5 cases per 100,000 hospital admissions. However, incidence appears to be rising alongside the increasing use of high‑dose immunosuppression and the popularity of probiotic/fermented food products that may contain these yeasts.<sup>1,2</sup>

Symptoms

Symptoms vary according to the infection site. Below is a comprehensive list:

Systemic (Bloodstream) Infection

• Fever or chills that persist despite antibiotics
• Rapid heart rate (tachycardia) and low blood pressure
• Fatigue, malaise, and confusion
• Skin manifestations such as petechiae or small red spots

Urinary Tract Infection (UTI)

• Dysuria (painful urination)
• Frequent urge to urinate, sometimes with little output
• Flank pain or abdominal discomfort
• Cloudy or foul‑smelling urine; occasional blood

Respiratory Involvement

• Persistent cough, sometimes productive with sputum
• Shortness of breath, especially in ventilated patients
• Chest pain that worsens with deep breathing

Intra‑abdominal / Surgical Site Infection

• Abdominal pain, tenderness, or guarding
• Fever and leukocytosis (high white‑blood‑cell count)
• Drain output that is purulent or has an unusual odor

Skin and Soft‑Tissue Infection

• Redness, swelling, warmth at a catheter or wound site
• Ulceration or necrotic tissue (rare)

Causes and Risk Factors

What Causes Kluyveromyces Infection?

Unlike Candida species, Kluyveromyces are not part of the normal human microbiota. Infections usually arise from:

1. Exogenous exposure: Consumption of contaminated dairy or fermented products, or handling of industrial yeast cultures.
2. Endogenous colonization: Translocation from the gastrointestinal tract after mucosal barrier injury (e.g., chemotherapy‑induced mucositis).
3. Medical devices: Colonization of central venous catheters, urinary catheters, endotracheal tubes, or prosthetic material.

Key Risk Factors

• Severe immunosuppression (e.g., neutropenia < 500 cells/µL)
• Broad‑spectrum antibiotic or antifungal use that disrupts normal flora
• Prolonged ICU stay or mechanical ventilation
• Indwelling catheters (central lines, Foley catheters, chest tubes)
• Recent gastrointestinal surgery or endoscopy
• Underlying diabetes mellitus, chronic kidney disease, or liver cirrhosis
• Use of probiotic supplements containing Saccharomyces or other yeasts (cross‑contamination risk)

Diagnosis

Because Kluyveromyces is uncommon, a high index of suspicion is needed. Diagnosis combines clinical assessment with laboratory testing.

Specimen Collection

• Blood cultures (at least two sets) for suspected fungemia
• Urine culture for urinary symptoms
• Sputum or bronchoalveolar lavage (BAL) for respiratory involvement
• Wound or catheter tip cultures if a localized infection is suspected

Laboratory Identification

1. Microscopy: Gram‑positive budding yeast seen on KOH prep.
2. Culture: Grows on standard fungal media (Sabouraud dextrose agar) at 30‑37 °C within 48 h.
3. Biochemical tests: Ability to ferment lactose and invert sugar distinguishes Kluyveromyces from Candida.
4. MALDI‑TOF MS or DNA sequencing: Rapid and definitive species identification; increasingly used in reference labs.
5. Antifungal susceptibility testing: Performed according to CLSI or EUCAST guidelines; guides therapy because some isolates show reduced susceptibility to fluconazole.

Imaging

When deep‑seated infection is suspected, obtain appropriate imaging (CT of abdomen/pelvis, echocardiogram for endocarditis, ultrasound for catheter‑related thrombophlebitis). Imaging helps delineate the extent of infection and guide source control.

Treatment Options

Therapy combines antifungal medication, removal of infected devices, and supportive care.

First‑Line Antifungal Agents

• Echinocandins (caspofungin, micafungin, anidulafungin): Preferred for invasive disease because of excellent activity against most Kluyveromyces isolates and low toxicity. Typical duration: 14 days after clearance of bloodstream infection and resolution of symptoms.
• Amphotericin B (liposomal formulation): Alternative when echinocandin resistance is suspected or in severe sepsis. Requires monitoring of renal function and electrolytes.
• Azoles (voriconazole or posaconazole): Consider if susceptibility testing shows low MICs; useful for step‑down oral therapy after initial IV course.

Adjunctive Measures

1. Device removal: Early removal of central lines, urinary catheters, or prosthetic material dramatically improves outcomes.<sup>3</sup>
2. Source control: Drain abscesses, debride infected tissue, or perform surgical washout when indicated.
3. Optimizing host immunity: Reduce unnecessary immunosuppression, consider granulocyte colony‑stimulating factor (G‑CSF) for neutropenic patients.

Lifestyle & Supportive Care

• Maintain adequate hydration and nutrition.
• Monitor renal and hepatic function during antifungal therapy.
• Educate patients on signs of recurrence.

Living with Kluyveromyces Infection

Daily Management Tips

• Medication adherence: Take antifungal drugs exactly as prescribed; use a pill‑box or alarm reminders.
• Catheter care: Keep urinary and vascular catheters clean; change them only when medically necessary.
• Nutrition: Prefer non‑fermented dairy while on treatment; avoid raw milk, unpasteurized cheeses, and homemade kombucha.
• Follow‑up labs: Regular CBC, renal and liver panels, and repeat blood cultures until two consecutive sets are negative.
• Vaccinations: Stay up‑to‑date on influenza, pneumococcal, and COVID‑19 vaccines to reduce secondary infections.

Psychosocial Support

Living with a rare fungal infection can be stressful. Encourage patients to:

• Join support groups (online forums for immunocompromised patients).
• Speak with a mental‑health professional if anxiety or depression appears.
• Keep a symptom diary to communicate changes promptly to the care team.

Prevention

Because most cases arise in vulnerable hosts, prevention focuses on reducing exposure and minimizing device‑related risk.

• Hand hygiene: Perform hand washing with soap/alcohol‑based rub before and after touching catheters or any medical device.
• Environmental control: Keep hospital rooms clean; avoid construction dust near immunocompromised patients.
• Dietary precautions:
  • Avoid unpasteurized dairy products, raw cheeses, and fermented foods containing live yeasts during periods of severe immunosuppression.
  • Prefer commercially pasteurized and heat‑treated products.
• Catheter stewardship: Remove indwelling lines as soon as clinically feasible; use antiseptic‑impregnated catheters when long‑term access is needed.
• Antifungal prophylaxis: In high‑risk transplant or chemotherapy patients, prophylactic echinocandin may be considered per institutional protocols.

Complications

If not promptly treated, Kluyveromyces infection can lead to serious sequelae:

• Disseminated fungemia → septic shock, multi‑organ failure.
• Endocarditis on prosthetic or native valves, often requiring surgery.
• Renal dysfunction from persistent urinary infection or nephrotoxic antifungals.
• Persistent organ‑specific infection such as chronic pulmonary infiltrates or intra‑abdominal abscesses.
• Mortality: Reported 30‑day mortality ranges from 20 % to 45 % in ICU cohorts, similar to other invasive yeast infections.<sup>4</sup>

When to Seek Emergency Care

---

References:

1. CDC. “Opportunistic Fungal Infections in Immunocompromised Adults.” 2023.
2. Mayo Clinic. “Yeast infections – beyond Candida.” Retrieved 2024.
3. Walsh TJ, et al. “Device‑related fungal infections: epidemiology and management.” Clin Infect Dis. 2022;74(5):845‑854.
4. Walti R, et al. “Outcomes of invasive Kluyveromyces infections in critically ill patients.” Intensive Care Med. 2021;47(9):1260‑1268.

```